Adalimumab-Induced Acute Myelogenic Leukemia
Document Type
Article
Publication Date
12-1-2008
Description
Newer biological treatment strategies have been developed in the last decade with some promising outcomes. Their safety, however, has been questioned lately with multiple reports of increased risk for malignancies and infectious complications. These reports render their use suboptimal. We report a 44-year-old woman receiving adalimumab (Humira®) for advanced juvenile rheumatoid arthritis who then developed acute myelogenic leukemia.
Citation Information
Saba, Nakhle; Kosseifi, Semaan G.; Charaf, Edris A.; and Hammad, Ahmad N.. 2008. Adalimumab-Induced Acute Myelogenic Leukemia. Southern Medical Journal. Vol.101(12). 1261-1262. https://doi.org/10.1097/SMJ.0b013e318188950a PMID: 19005432 ISSN: 0038-4348